JP Morgan Chase’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-649,231
| Closed | -$24.5M | – | 6842 |
|
|
2021
Q1 | $24.5M | Buy |
649,231
+480,496
| +285% | +$12M | ﹤0.01% | 1581 |
|
|
2020
Q4 | $2.87M | Sell |
168,735
-33,967
| -17% | -$426K | ﹤0.01% | 3235 |
|
|
2020
Q3 | $928K | Buy |
202,702
+14,294
| +8% | +$72.6K | ﹤0.01% | 3686 |
|
|
2020
Q2 | $1.15M | Sell |
188,408
-15,813
| -8% | -$65.1K | ﹤0.01% | 3426 |
|
|
2020
Q1 | $463K | Sell |
204,221
-324,967
| -61% | -$1.38M | ﹤0.01% | 3852 |
|
|
2019
Q4 | $2.43M | Buy |
529,188
+123,507
| +30% | +$489K | ﹤0.01% | 3241 |
|
|
2019
Q3 | $1.57M | Buy |
405,681
+83,774
| +26% | +$460K | ﹤0.01% | 3563 |
|
|
2019
Q2 | $1.95M | Buy |
321,907
+78,404
| +32% | +$750K | ﹤0.01% | 3399 |
|
|
2019
Q1 | $3.26M | Sell |
243,503
-2,072
| -0.8% | -$23.6K | ﹤0.01% | 2952 |
|
|
2018
Q4 | $2.28M | Sell |
245,575
-12,077
| -5% | -$144K | ﹤0.01% | 3188 |
|
|
2018
Q3 | $3.59M | Buy |
257,652
+16,863
| +7% | +$251K | ﹤0.01% | 3019 |
|
|
2018
Q2 | $3.81M | Sell |
240,789
-112,218
| -32% | -$1.96M | ﹤0.01% | 2899 |
|
|
2018
Q1 | $6.06M | Sell |
353,007
-29,016
| -8% | -$566K | ﹤0.01% | 2410 |
|
|
2017
Q4 | $8.37M | Buy |
382,023
+96,660
| +34% | +$3.11M | ﹤0.01% | 2266 |
|
|
2017
Q3 | $11.1M | Sell |
285,363
-13,032
| -4% | -$409K | ﹤0.01% | 1906 |
|
|
2017
Q2 | $8.98M | Buy |
298,395
+184,888
| +163% | +$5.77M | ﹤0.01% | 2046 |
|
|
2017
Q1 | $4.1M | Sell |
113,507
-41,993
| -27% | -$1.85M | ﹤0.01% | 2567 |
|
|
2016
Q4 | $7.79M | Buy |
155,500
+25,725
| +20% | +$1.35M | ﹤0.01% | 2100 |
|
|
2016
Q3 | $6.81M | Buy |
129,775
+49,146
| +61% | +$2.35M | ﹤0.01% | 2036 |
|
|
2016
Q2 | $3.33M | Buy |
80,629
+80,475
| +52,256% | +$3.5M | ﹤0.01% | 2534 |
|
|
2016
Q1 | $6K | Hold |
154
| – | – | ﹤0.01% | 4349 |
|
|
2015
Q4 | $6K | Buy |
+154
| New | +$5.16K | ﹤0.01% | 4316 |
|
|
2014
Q4 | – | Sell |
-16,791
| Closed | -$197K | – | 4421 |
|
|
2014
Q3 | $197K | Buy |
+16,791
| New | +$212K | ﹤0.01% | 4003 |
|
JP Morgan Chase's FPRX Position: Q2 2021 in Review
JP Morgan Chase sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 649,231 shares — an estimated $24.5M sold.
JP Morgan Chase first reported a position in FPRX in Q3 2014 and held it in 23 quarters. The position peaked at $24.5M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- JP Morgan Chase reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- JP Morgan Chase sold 649,231 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $24.5M.
- JP Morgan Chase first reported a position in Five Prime Therapeutics, Inc. in Q3 2014 and held it in 23 quarters.
- JP Morgan Chase's Five Prime Therapeutics, Inc. position peaked at $24.5M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on JP Morgan Chase's 13F filing for Q2 2021, filed 12 Aug 2021.